Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01412229|
Recruitment Status : Completed
First Posted : August 9, 2011
Results First Posted : July 2, 2017
Last Update Posted : November 23, 2020
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Head and Neck Cancer||Drug: Cetuximab Drug: Nab-paclitaxel Drug: Carboplatin||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Study of Carboplatin, Nab-paclitaxel and Cetuximab for Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck|
|Study Start Date :||February 2012|
|Actual Primary Completion Date :||June 20, 2015|
|Actual Study Completion Date :||December 2019|
Weekly cetuximab given intravenously for 6 weeks during induction chemotherapy and continue during the 2-3 week break prior to definitive chemoradiotherapy.
Other Name: Erbitux
Weekly nab-paclitaxel given intravenously following cetuximab infusion for 6 weeks.
Other Name: Abraxane
Weekly carboplatin given intravenously following nab-paclitaxel infusion for 6 weeks.
Other Name: Paraplatin
- Clinical Response Rate Following Induction Chemotherapy [ Time Frame: 9 weeks ]Evaluation of target lesions via imaging with CT or MRI scans at 2-3 weeks post induction chemotherapy. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions.
- Rate of Complete Response Following Induction Chemotherapy [ Time Frame: Baseline evaluation to 3 weeks after induction chemotherapy ]Report the rate of complete responses, defined as disappearance of all target lesions, following induction chemotherapy. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions.
- Progression Free Survival [ Time Frame: 1 year ]Rate of Progression Free Survival (Time to death or progression defined by imaging of target lesions via CT or MRI scan post induction chemotherapy and chemoradiotherapy every 3 months for one year)
- Objective Response Rate (CR+PR) [ Time Frame: 20 weeks ]Objective Response Rate as defined by RECIST 1.1 after induction chemotherapy followed by definitive chemoradiation. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Objective Response (OR) = CR + PR.
- Complete Response Rate (CR) [ Time Frame: 20 weeks ]Complete Response Rate as defined by RECIST 1.1 after induction chemotherapy followed by definitive chemoradiation
- Overall Survival [ Time Frame: 1 year ]Rate of Overall Survival
- Number of Participants With at Least One Grade 3-4 Toxicity [ Time Frame: 9 Weeks ]Toxicity will be assessed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.
- Number of Participants With at Least One Grade 3-4 Toxicity, Listed by Event [ Time Frame: 24 Weeks ]Toxicity will be assessed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.
- Patient-reported Quality of Life Scores [ Time Frame: screening until one year after treatment ]Functional Assessment of Cancer Therapy - Head & Neck (FACT-HN) is the FACT-G and a 12 item head and neck cancer specific subscale completed at screening (Screening), 3 weeks post induction chemotherapy (Treatment Break), 7 weeks post concomitant chemoradiotherapy (7 weeks Off Treatment), one year post off-treatment (1 year Off Treatment). The FACT-G is a 27 item measure of general QOL assessing function in 4 domains: physical well-being (PWB), social-family well-being (SFWB), emotional well-being (EWB) and functional well-being (FWB). Items are rated by patients on a Likert scale from 0 to 4 (resulting in potential total scores between 0 and 156). Higher scores represent better QOL.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Histologically or cytologically confirmed SCCHN or poorly differentiated or undifferentiated cancer of the head and neck.
- Measurable disease.
- All primary sites are eligible excluding nasopharyngeal.
Surgically unresectable and/or N2b or greater nodal disease; Note: surgical unresectability will be defined as the combination of the treating surgeon's judgment of unresectability plus one of the following objective criteria:
- Encasement of tumor or nodes to the carotid artery or ¾ encasement of the carotid artery.
- Involvement of prevertebral musculature
- Invasion of the bone of the skull base
- Need for glossectomy or extensive glossal resection where functional outcome is considered unacceptable to surgeon or patient
- Involvement of the cervical spine
- Severe, unacceptable functional deficit that would result from any proposed definitive surgical resection.
- ECOG performance status 0-1
- Chemotherapy: No prior chemotherapy for the treatment of SCCHN.
- Platinum chemotherapy: No previous history of carboplatin or cisplatin therapy.
- Nab-paclitaxel: No previous treatment with nab-paclitaxel or another taxane.
- Cetuximab: No previous treatment with cetuximab Or another epidermal growth factor receptor (EGFR) inhibitor.
- Radiation therapy: No prior radiation to the head and neck region.
- Age > or = 18 years. Men and women are eligible for participation.
Must have acceptable organ and marrow function as defined below. Laboratory tests should be completed within 14 days prior to registration:
- Absolute Neutrophil Count (ANC) > or = 1,500/mm3
- Platelets > or = 100,000/mm3
- Hemoglobin (Hgb) > 9g/dL
- Total bilirubin < or = 1.5mg/dL
- Albumin > 2.5 g/dL
- Aspartate aminotransferase (AST)/Alanine Aminotransferase (ALT) < or = 2.5 times institutional upper limit of normal, alkaline phosphatase < 2.5 x upper limit of normal, glomerular filtration rate (GFR) > 30 mL/min (by standard Cockcroft and Gault formula or measured via 24 hour urine collection)
- No pre-existing neuropathy greater than grade I
- Women of childbearing potential must have a negative serum or urine pregnancy test performed within 7 days prior to day 1 of study treatment.
- Women of childbearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation and for three months after completing treatment. Adequate contraception is defined as any medically recommended method (or combination of methods) as per standard of care.
- Patients must have the ability to understand and the willingness to sign a written informed consent document.
- Patients must have a negative result for preformed immunoglobulin E (IgE) antibodies to galactose-alpha-1,3,-galactose.
- Prior treatment with any of the study medications.
- Prior radiation to any of the field required to treat the tumor.
- Any metastatic disease.
- The patient may have had a prior malignancy but must be disease-free for three years prior to study entry. A history of superficial non-melanoma skin cancer or in situ carcinoma of the cervix less than three years will be allowed.
- Pregnant or lactating female
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring IV antibiotics, or psychiatric illness/social situations that would limit compliance with study requirements. Cardiac disease such as symptomatic congestive heart failure, unstable angina pectoris, or myocardial infarction will result in exclusion only if active within the past six months. Cardiac dysrhythmia will only result in exclusion if active and symptomatic (for example, rate-controlled atrial fibrillation will not result in exclusion).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01412229
|United States, North Carolina|
|University of North Carolina at Chapel Hill|
|Chapel Hill, North Carolina, United States, 27599|
|United States, Tennessee|
|Nashville, Tennessee, United States, 37232|
|United States, Washington|
|University of Washington|
|Seattle, Washington, United States, 98194|
|Principal Investigator:||Jared Weiss, MD||University of North Carolina, Chapel Hill|
|Responsible Party:||UNC Lineberger Comprehensive Cancer Center|
|Other Study ID Numbers:||
|First Posted:||August 9, 2011 Key Record Dates|
|Results First Posted:||July 2, 2017|
|Last Update Posted:||November 23, 2020|
|Last Verified:||September 2020|
Head and neck cancer
Carcinoma, Squamous Cell
Head and Neck Neoplasms
Squamous Cell Carcinoma of Head and Neck
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Squamous Cell
Neoplasms by Site
Antineoplastic Agents, Phytogenic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Immunological